Anzeige
Mehr »
Login
Mittwoch, 01.05.2024 Börsentäglich über 12.000 News von 686 internationalen Medien
Paukenschlag in USA: Cannabis-Neuregulierung durch DEA sorgt für Kursexplosion!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
27 Leser
Artikel bewerten:
(0)

Research and Markets - Global Travel Vaccines Market 2016-2020: Market Growth at CAGR of 6.83% - Growing Demand Among Travelers / Additional Age Group Approval / Inclusion in NIP

DUBLIN, Dec 9, 2016 /PRNewswire/ --

Research and Markets has announced the addition of the "Global Travel Vaccines Market 2016-2020" report to their offering.

The global travel vaccines market to grow at a CAGR of 6.83% during the period 2016-2020.

The report covers the present scenario and the growth prospects of the global travel vaccines market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of various vaccines administered to actively immunize meningococcal disease, Japanese encephalitis, rabies, typhoid, yellow fever, hepatitis B, and hepatitis A.

The report also considers the revenues to be generated from the sales of vaccines that are expected to be launched into the market during the forecast period. The report also includes a discussion of the key vendors operating in this market.

As the world continues to move toward globalization, the international travels will keep increasing. This fuels the demand for travel vaccines as the prevalence of infectious diseases are specifically region prone, unlike that of other indications. As vaccines are largely used as a preventive measure against these known infectious diseases, the travelers are advised to follow the region-specific immunization plan.

The market is growing because various government bodies have mandated the immunization of travelers visiting the infectious-prone areas with various types of vaccines. This, in turn, prevents the spread of infection and averts any chances of epidemic outbreaks.

Key vendors

  • GlaxoSmithKline
  • Merck
  • Pfizer
  • Sanofi

Other prominent vendors

  • Abbott
  • AstraZeneca
  • Bavarian Nordic
  • Baxter
  • Beijing Minhai Biotechnology
  • Bharat Biotech
  • Bharat Immunologicals and Biologicals
  • Bio-Med
  • Seqirus CSL
  • Crucell
  • CSL
  • Dynavax Technologies
  • Emergent BioSolutions
  • GlycoVaxyn
  • GreenSignal Bio Pharma
  • Hualan Biological Engineering
  • Imunoloski Zavod
  • Indian Immunologicals
  • Janssen Pharmaceuticals
  • LG Life Sciences
  • Lupin
  • Mitsubishi Tanabe Pharma
  • Novavax
  • Nuron Biotech
  • Panacea Biotec
  • Pfizer
  • Protein Sciences
  • Roche
  • SK Chemicals
  • Sinovac Biotech
  • Takeda Pharmaceutical
  • Vacunas Finlay
  • Valeant Pharmaceuticals
  • Valneva,
  • Zydus Cadila

Key Topics Covered:

Part 01: Executive summary

Part 02: Scope of the report

Part 03: Market research methodology

Part 04: Introduction

Part 05: Regulatory scenario of vaccines

Part 06: Market landscape

Part 07: Market segmentation by disease type

Part 08: Market segmentation by composition

Part 09: Geographical segmentation

Part 10: Market drivers

Part 11: Impact of drivers

Part 12: Market challenges

Part 13: Impact of drivers and challenges

Part 14: Market trends

Part 15: Vendor landscape

Part 16: Key vendor analysis

Part 17: Appendix

For more information about this report visit http://www.researchandmarkets.com/research/jbvvww/global_travel

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Kupfer - Jetzt! So gelingt der Einstieg in den Rohstoff-Trend!
In diesem kostenfreien Report schaut sich Carsten Stork den Kupfer-Trend im Detail an und gibt konkrete Produkte zum Einstieg an die Hand.
Hier klicken
© 2016 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.